AwardTape · Defense awards · Medical · Health care services · HT001425P0034
HT001425P0034: $45K purchase order to Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation holds a purchase order from Defense Health Agency with $45K obligated since Oct 2023, against a ceiling of $224K. Latest action Nov 26, 2025.
Clonoseq has received clearance from the food and drug administration for an in vitro diagnostic test service that detects blood cancer in patients.
| PIID | HT001425P0034 |
|---|---|
| Type | purchase order |
| Company | Adaptive Biotechnologies Corporation |
| Agency | Defense Health Agency |
| Contracting office | DEFENSE HEALTH AGENCY |
| Category | Medical · Health care services |
| PSC | Q301 REFERENCE LABORATORY TESTING |
| NAICS | 621511 MEDICAL LABORATORIES |
| Obligated since Oct 2023 | $45K |
| Total obligated (lifetime) | $45K |
| Ceiling (base and all options) | $224K |
| Base date | Feb 28, 2025 |
| Latest action | Nov 26, 2025 |
| End date | Feb 27, 2030 |
| Actions since Oct 2023 | 4 |
| Pricing | Firm fixed price |
| Competition | Competed under simplified acquisition |
| Place of performance | MD |
| Source | USAspending.gov record |
| Reporting lag | DoD 90 days |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Place of performance shows the state only.
Terminal: alerts on new orders and modifications to this contract, and CSV export.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial